Marijuana Milestone: FDA Approval for Epilepsy Treatment

You are receiving this email as a part of your subscription to Strategic Tech Investor. If you have any questions or would like to change your email settings, please reference the contact information at the bottom of this email. [Strategic Tech Investor] TODAY'S TOP HEADLINES: [weed]( [Landmark FDA Approval Could Change Marijuana Industry Completely]( The FDA just approved its first ever cannabis-based seizure drug, Epidiolex, to treat children with rare forms of epilepsy. This marks a tremendous milestone because not only for the company and the marijuana industry, but for you. There is expected to a historic market movement following the FDA's decision. Analysts have suggested Epidiolex will become a blockbuster drug - one which earns its manufacturer [more than $1 billion a year](. With marijuana gaining increased credibility by the day, and U.S. midterm elections fast approaching, this could bring about a new wave of legalization. By learning how to align your investments in this industry with what's happening on the ground level, you have the chance to turn this marijuana milestone into a million-dollar fortune. [Click here]( to find out more. --------------------------------------------------------------- [scientist]( [This Pharma Player's $90 million Breakthrough Could Soon Double the Market's Return]( We're coming up on the one-year anniversary of an event set to have a big impact on the future of drug discovery. And yet, it flew right under Wall Street's radar screen. Maybe that's because a $90 million investment seems like small potatoes for the global drug industry - one that Evaluate Pharma says will be worth $1.1 trillion by 2022. Here's the thing though. This Big Pharma player said last June 21 that it had reopened its Biotechnology Center in San Diego after a big upgrade. That event got scant attention beyond in the local press. But it should have. Why? This new facility may very well mark the drug industry's research tipping point. [Check it out](... --------------------------------------------------------------- [boxing]( [How the "Tariff Tantrums" Will Blow Over]( Here are a few things markets don't like: Geopolitical leadership that doesn't follow a logical path...Uncertainty of any kind...The prospect of contracting economies...On Monday, we got truckloads of all three. And they all came from the trade war news headlines. The effect was self-reinforcing - and profound. And, as we've seen, when emotion enters the process, traders and investors get worried that it could add to the uncertainty. So the big question before every investor this week is: Is this all coincidence? Or is the "Trump growth" narrative asserting its dominance? My colleague, D.R. Barton, Jr., thinks it's the latter, and he'll show you why that's important with a few charts here...[Check it out](... --------------------------------------------------------------- [calculator]( [WARNING: Social Security Accounting Errors Leaves Tens of Thousands Underpaid]( Three audits by the U.S. Inspector General have uncovered startling account errors by the Social Security Administration. Millions of dollars have been left unpaid. In fact, you could be owed as much as $23,441. [Details here](. --------------------------------------------------------------- [oil] The Most Profitable Oil Company Is on Sale: Here's What to Do [PROFIT OPPORTUNITY] Oil prices fall, leaving many investors scrambling. Fortunately, that puts one company "on sale," and our Chief Investment Strategist, Keith Fitz-Gerald, is giving an exclusive recommendation. You'll even receive a simple, proven formula to make this one of your next big wins and capitalize on all future oil companies as well. Don't miss out. To access Keith's special report and be first to receive updates like this for all future plays, subscribe to Total Wealth Research by [clicking here](. --------------------------------------------------------------- [pills]( [U.S. FDA Approves First Marijuana-based Pharmaceutical]( The U.S. Food and Drug Administration (FDA) smashed the glass ceiling when it comes to cannabis. The agency has approved the first cannabis-based drug in its history...It comes in the wake of Canada's full legalization of marijuana last week, and with 16 U.S. states deciding on legalization measures this year. The news is huge for GW Pharma, and for the broader cannabis-based medicine industry in general, as the regulatory door has now swung wide open. And now with GW's approval, the template has been set for pharmaceutical companies - several of which have been in my model trading portfolio for more than a year. [Click here](... --------------------------------------------------------------- [plug]( [California's Saying Goodbye to Electric Bills Forever (You Can Too)!]( A stunning breakthrough in chemical engineering has unleashed a 36,000-year supply of free energy. And utility companies are OUTRAGED. This could single-handedly put an end to your monthly electric bills, saving thousands of dollars each year for millions of American homeowners. And California is leading the way, with an upcoming vote to mandate this new technology that could have residents saying goodbye to electric bills. To find out how your family can take full advantage, [click here](. --------------------------------------------------------------- [umbrella]( [A Survival Guide to the Worst Market Apocalypse: Part I]( We just raised interest rates for the second time this year. Now, we're expected to raise them two more times. Is it time to start worrying yet? It must be time to worry. Popular economic theory dictates that rising rates make fixed-income investments more attractive than equities. Investors will sell stocks and buy bonds, being the rational, thoughtful folks they are all the time. The folks on TV looked pretty worried about it. I should be as well, right...? When it comes to worrying, my colleague, Tim Melvin's motto is go big or go home. That's because he's been in this game for over three decades, and he's profited handsomely through some of the most worrisome times in the history of the United States. [Learn how](... --------------------------------------------------------------- [email] This Industry Is Creating Billionaires... and You Could Be Next It's no secret that more millionaires and billionaires come out of technology than any other sector in the market... and carving out your share of this wealth has never been easier. Capitalize on these windfall profits by [clicking here](. You'll begin to receive the hottest, most "under-the-radar" tech opportunities sent straight to your inbox the moment we release them --------------------------------------------------------------- You are receiving this e-mail at, {EMAIL}, as a part of your free subscription to Strategic Tech Investor. Remove your email from this list: [Unsubscribe]( To cancel by mail or for any other subscription issues, write us at: Strategic Tech Investor | Attn: Member Services | 1125 N Charles Street | Baltimore, MD 21201 North America: 888.384.8339; International: 443.353.4519; Fax: 410.622.3050 [Contact Customer Service]( Website: []( © 2018 Strategic Tech Investor All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of: Strategic Tech Investor. 1125 N Charles Street, Baltimore MD 21201.